Short seller Scorpion Capital disclosed a short position in TransMedics Group Inc (NASDAQ:TMDX) accusing the organ transplant ...

Barclays says reports of Eli Lilly (LLY) reportedly being in talks to acquire Scorpion Therapeutics has a positive read-through to Relay ...

Scorpion’s drug candidate inhibits a mutation that is a major driver of breast, gynaecological and head and neck cancers ...

Eli Lilly (LLY) is in advanced talks to buy cancer-focused biotech Scorpion Therapeutics in a deal worth up to $2.5B, people close to the talks ...

Shares of TransMedics Group ( TMDX -12.34%) were tanking 14.3% lower as of 10:46 a.m. ET on Friday. The big sell-off came after activist short seller Scorpion Capital released a scathing report about ...

STX-478 is under clinical development by Scorpion Therapeutics and currently in Phase II for Endometrial Cancer.